U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

The drugmaker Ely Lilly (NYSE: LLY) has had a very successful run over the long run. Shares currently trade around $818 and ...

Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and Services Administration for blocking a plan to change its 340B program from immediate discounts to offering ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...

Eli Lilly & Co. will set up a S$42 million ($31 million) digital health innovation hub in Singapore, expanding its research ...